Feature | Atrial Fibrillation | November 02, 2017

Mixed Results in PREVAIL Trial Comparing Five-Year Data for LAA Closure Compared to Warfarin

Study looked at patients with nonvalvular atrial fibrillation and included a combined meta-analysis with PROTECT AF at TCT 2017 

The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.

November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority. However, the second co-primary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority. When combined with the five-year outcomes of the PROTECT AF trial a meta-analysis demonstrated that LAAC provides stroke prevention comparable to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke and mortality.

Findings were reported at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and published simultaneously in the Journal of the American College of Cardiology.

“Beyond PROTECT AF, PREVAIL is the only other completed randomized clinical trial comparing any LAAC device with an oral anticoagulant,” said Saibal Kar, M.D., director of cardiovascular intervention center research at Cedars-Sinai Medical Center. “Based on the combined results of these two studies, left atrial appendage closure is a reasonable strategy for stroke prophylaxis for patients who are poor candidates for long-term oral anticoagulation.”

Because of identical efficacy endpoint definitions in both the PROTECT AF and PREVAIL trials, and the near-identical eligibility criteria, data from both trials were pooled for a patient-level meta-analysis. The PROTECT AF and PREVAIL trials enrolled 707 and 407 patients, respectively, who were randomized 2:1 to the LAAC and warfarin arms. In both trials, patients were followed for the protocol-defined maximum time period of five years, ending in 2013 and 2017. Baseline patient characteristics were similar in both studies.

For the PREVAIL trial, all endpoints required the inclusion of the PROTECT AF informative prior, resulting in a calculated 18-month rate of the first coprimary endpoint (composite of stroke, systemic embolism (SE), or cardiovascular/unexplained death) of 0.066 with LAAC versus 0.051 for warfarin, yielding a mean 18-month rate ratio of 1.33 (95% credible interval: 0.78 to 2.13). It did not achieve noninferiority (posterior probability for noninferiority = 88.4%). However, the second coprimary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority (posterior probability for noninferiority = 97.5%). The calculated 18-month rate for the second coprimary efficacy endpoint was 0.0255 in the LAAC group versus 0.0135 in the warfarin group (rate difference 0.0120; 95% credible interval: -0.0036 to 0.0275) At five years, the warfarin arm maintained an unexpectedly low ischemic stroke rate (0.73%), as compared with other studies examining such a regimen.

In the meta-analysis of PROTECT AF and PREVAIL with five-year follow-up, the composite endpoint was similar between groups (HR: 0.820; P=0.27), as were all-stroke/SE (HR: 0.961; P= 0.87). The ischemic stroke/SE rate was numerically higher with LAAC, but this difference did not reach statistical significance (HR: 1.71; P=0.080). However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-cause death, and post-procedure bleeding favored LAAC (HR: 0.20; P=0.0022; HR: 0.45; P=0.03; HR: 0.59; P=0.027; HR: 0.73; P=0.035; HR: 0.48; P=0.0003, respectively). Therefore, the meta-analysis demonstrates comparable efficacy and stroke rates with no significant difference across subgroups, no significant differences in ischemic stroke rates versus warfarin, and significant, superior reductions in disabling strokes, non-procedural bleeding, and mortality.

The PREVAIL trial was funded by Boston Scientific. Kar reported that he received research grants from and served as a consultant for Abbott Vascular and Boston Scientific; has served as a member of the advisory board for left atrial appendage closure; is the national principal investigator of the Continuous Access Registries (CAP & CAP2); and has served as a proctor for Boston Scientific.

For more information: www.crf.org

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

Related Content

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Overlay Init